SAR445399 Clinical Trials (2026): 2 Studies for Hidradenitis Suppurativa & Non-cystic Fibrosis Bronchiectasis

Hipa.ai Research · Source: ClinicalTrials.gov / AACT

Synced daily from ClinicalTrials.gov via AACT. Last sync: .

2 SAR445399 clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 2 indications (including Hidradenitis Suppurativa & Non-cystic Fibrosis Bronchiectasis) and 214 total planned enrollment. 2 SAR445399 clinical trials are actively recruiting at 19 U.S. sites across 9 states. Most recent activity: NCT07547436 (Aug 2028).

Where to Participate: All SAR445399 Trial Sites in the U.S. (19 sites across 9 states)

Every actively recruiting SAR445399trial site, sorted by state then city. Each row links to the trial detail page (eligibility, contacts, full study record). Sites no longer enrolling at the location level are excluded. ClinicalTrials.gov / AACT does not provide street-level addresses; the map link uses the facility's geocoded coordinates where available.

StateFacilityCityTrialMap
AZScottsdale Clinical Trials- Site Number : 8400006Scottsdale85260NCT07225569Map
CACarbon Health - North Hollywood - NoHo West- Site Number : 8400017North Hollywood91606NCT07225569Map
FLEncore Medical Research of Boynton Beach- Site Number : 8400005Boynton Beach33436NCT07225569Map
FLFXM Clinical Research - Fort Lauderdale- Site Number : 8400013Fort Lauderdale33308NCT07225569Map
FLAlliance for Multispeciality Research - Fort Myers- Site Number : 8400007Fort Myers33912NCT07225569Map
FLEncore Medical Research - Hollywood- Site Number : 8400004Hollywood33024NCT07225569Map
FLAdvanced Pulmonary Research Institute- Site Number : 8400001Loxahatchee Groves33470NCT07547436Map
FLFlorida International Research Center- Site Number : 8400002Miami33173NCT07225569Map
FLFlorida Research Center- Site Number : 8400009Miami33174NCT07225569Map
FLFxm Clinical Research/Fax Pharma Clinical Research- Site Number : 8400014Miami33146NCT07225569Map
FLHull and Hull Medical Specialists- Site Number : 8400002Plantation33324NCT07547436Map
FLAdvanced Clinical Research Institute- Site Number : 8400021Tampa33607NCT07225569Map
GACleaver Medical Group Dermatology- Site Number : 8400008Cumming30040NCT07225569Map
GAFirst Georgia Physician Group- Site Number : 8400033Fayetteville30214NCT07225569Map
KSEssential Medical Research- Site Number : 8400015Overland Park66213NCT07225569Map
KYDermatology Specialists Research (DS Research) - Kentucky- Site Number : 8400026Louisville40241NCT07225569Map
NYEquity Medical- Site Number : 8400010New York10023NCT07225569Map
PAClinical Research Associates of Central Pennsylvania- Site Number : 8400006DuBois15801NCT07547436Map
TXElligo Health Research/The Woodlands Dermatology Associates- Site Number : 8400020The Woodlands77380NCT07225569Map

SAR445399 clinical trials at a glance: phase × recruitment status

PhaserecruitingTotal
P222

Recruiting SAR445399 clinical trials (2)

Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).

NCT IDTitlePhaseIndicationEnrollmentStarted
NCT07547436A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis BronchiectasisP2Non-cystic Fibrosis Bronchiectasis70Jun 2026
NCT07225569CLAROSA Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis SuppurativaP2Hidradenitis Suppurativa144Dec 2025

SAR445399 clinical trials by indication

Non-cystic Fibrosis Bronchiectasis (1)

NCTAcronymPhaseStatusTitle
NCT07547436P2recruitingA Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis Bronchiectasis

Hidradenitis Suppurativa (1)

NCTAcronymPhaseStatusTitle
NCT07225569CLAROSP2recruitingA Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis Suppurativa

SAR445399 pivotal trial highlights (Phase 2/3/4)

Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.

AcronymNCTPhaseStatusIndicationEnrollmentPubMed
CLAROSNCT07225569P2recruitingHidradenitis Suppurativa144

All SAR445399 trials (2)

Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.

NCT IDAcronymTitlePhaseStatusEnrollmentSponsorStarted
NCT07547436A Study to Access Activity and Safety With SAR445399 Compared With Placebo in Participants Aged 18 to 80 Years of Age With Non-Cystic Fibrosis BronchiectasisP2recruiting70SanofiJun 2026
NCT07225569CLAROSA Study to Investigate Efficacy and Safety With SAR445399 in Adult Participants With Moderate to Severe Hidradenitis SuppurativaP2recruiting144SanofiDec 2025

SAR445399 clinical trials: frequently asked questions

How many SAR445399 clinical trials are there?
2 SAR445399 clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 2 are actively recruiting participants.
Are SAR445399 clinical trials recruiting in 2026?
Yes — 2 SAR445399 trials are actively recruiting in 2026, with 19 U.S. sites across 9 states. See the recruiting trials and the per-state site list further down this page.
What conditions is SAR445399 being studied for?
SAR445399 is being studied for Hidradenitis Suppurativa, Non-cystic Fibrosis Bronchiectasis. The trials are grouped by indication on this page.
What phase is SAR445399 in?
SAR445399 clinical trials span 2 Phase 2. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
Who sponsors SAR445399 clinical trials?
The lead sponsor across the most SAR445399 trials is Sanofi. Each trial row links to the full study detail page including sponsor information.

Sources and methodology

Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming SAR445399as an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.

Last refreshed .

Related pages on Hipa.ai: